Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 21 points (0.1%) at 16,839 as of Wednesday, June 25, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,709 issues advancing vs. 1,282 declining with 166 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.2%. Top gainers within the industry include

Bristol-Myers Squibb Company

(

BMY

), up 3.1%,

Shire

(

SHPG

), up 3.1%,

AbbVie

(

ABBV

), up 2.5%,

Regeneron Pharmaceuticals

(

REGN

), up 2.5% and

Eli Lilly and

(

LLY

), up 1.2%. On the negative front, top decliners within the industry include

Grifols

(

GRFS

), down 2.1%, and

Actavis

(

ACT

), down 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Johnson & Johnson

(

JNJ

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Johnson & Johnson is up $0.90 (0.9%) to $105.49 on average volume. Thus far, 2.9 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 7.2 million shares. The stock has ranged in price between $104.23-$105.87 after having opened the day at $104.23 as compared to the previous trading day's close of $104.59.

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $297.8 billion and is part of the health care sector. Shares are up 14.2% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Johnson & Johnson

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Johnson & Johnson Ratings Report

now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading,

Pfizer

(

PFE

) is up $0.44 (1.5%) to $29.74 on average volume. Thus far, 15.0 million shares of Pfizer exchanged hands as compared to its average daily volume of 29.4 million shares. The stock has ranged in price between $29.15-$29.77 after having opened the day at $29.15 as compared to the previous trading day's close of $29.30.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. Pfizer has a market cap of $190.0 billion and is part of the health care sector. Shares are down 4.3% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Pfizer

as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Pfizer Ratings Report

now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading,

Gilead

(

GILD

) is up $0.64 (0.8%) to $81.45 on light volume. Thus far, 4.4 million shares of Gilead exchanged hands as compared to its average daily volume of 15.9 million shares. The stock has ranged in price between $80.60-$81.56 after having opened the day at $80.86 as compared to the previous trading day's close of $80.81.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $124.7 billion and is part of the health care sector. Shares are up 7.6% year-to-date as of the close of trading on Tuesday. Currently there are 16 analysts who rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Gilead Ratings Report

now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null